These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30052496)

  • 1. A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience.
    Neitzke-Spruill L; Glasser C
    J Psychoactive Drugs; 2018; 50(4):314-321. PubMed ID: 30052496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness.
    Roberts TB
    Adv Mind Body Med; 1999; 15(2):139-47. PubMed ID: 10367499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic drugs and mystical experience.
    Pahnke WN
    Int Psychiatry Clin; 1969; 5(4):149-62. PubMed ID: 4892137
    [No Abstract]   [Full Text] [Related]  

  • 5. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid.
    Kruger DJ; Bone CC; Meacham MC; Klein C; Kruger JS
    J Psychoactive Drugs; 2024; 56(4):563-567. PubMed ID: 37381980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
    Kangaslampi S; Hausen A; Rauteenmaa T
    J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychedelics and quasi-mystical experiences].
    Szummer C
    Lege Artis Med; 2012 Feb; 22(2):154-7. PubMed ID: 23057252
    [No Abstract]   [Full Text] [Related]  

  • 12. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts.
    Graziosi M; Singh M; Nayak SM; Yaden DB
    J Psychoactive Drugs; 2023; 55(5):558-569. PubMed ID: 37679890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique.
    Mosurinjohn S; Roseman L; Girn M
    Front Psychiatry; 2023; 14():1077311. PubMed ID: 37181886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic agents and mysticism.
    Moraczewski A
    Psychosomatics; 1971; 12(2):94-100. PubMed ID: 5172950
    [No Abstract]   [Full Text] [Related]  

  • 19. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
    J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.